Cherry Biotech is delighted to announce the entry into partnership with Cytion for the access to their 800+ cell lines catalog in the production of Cherry Biotech’s OrganoidPlate.
The partnership agreement is to open access to Cytion’s cell line catalog to Cherry Biotech product development. This partnership will allow the production of organoids with a high degree of human physiological relevancy and therefore contribute to the generation of real-life-like data by our customers during preclinical drug development phases.
“Partnering with Cytion is key to unlock the generation of real-life-like dataset by our customers, and to support their decision-making during drug development”, said Pierre Gaudriault, CBO of Cherry Biotech. We are delighted to partner with them and to provide authenticated, contamination-free cell lines as the reliable starting material for their organoid models, said Jonathan Steubing, CEO of Cytion.
Read the full press release : Cherry Biotech x Cytion partnership_03022026
